| Drug Name |
Prasugrel hydrochloride |
| Drug ID |
BADD_D01823 |
| Description |
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. |
| Indications and Usage |
Indicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding. |
| Marketing Status |
Prescription |
| ATC Code |
B01AC22 |
| DrugBank ID |
DB06209
|
| KEGG ID |
D05597
|
| MeSH ID |
D000068799
|
| PubChem ID |
10158453
|
| TTD Drug ID |
D07IRF
|
| NDC Product Code |
65597-601; 66039-887; 55111-928; 14501-0072; 65977-0076; 53747-048; 65597-602; 24196-177; 62756-786; 65015-809; 65862-809; 82245-0102 |
| Synonyms |
Prasugrel Hydrochloride | Hydrochloride, Prasugrel | Prasugrel HCl | HCl, Prasugrel | CS 747 | 747, CS | CS-747 | CS747 | Prasugrel | Efient | Effient | LY 640315 | 640315, LY | LY640315 | LY-640315 |
